PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 1, 1994Circulation274 citationsOpen Access

Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators.

View Full Paper
MBMichael R. BristowJOJohn B. O’ConnellEGEdward M. Gilbert

Key Points

  • This research aims to evaluate the dose-response relationship of chronic beta-blocker treatment with bucindolol in heart failure patients.
  • Investigated the effects of chronic beta-blocker therapy using bucindolol.

Structured PICO

Does chronic beta-blocker treatment with bucindolol improve left ventricular function in patients with heart failure from systolic dysfunction?

P
Population
Patients with heart failure from systolic dysfunction (idiopathic dilated or ischemic cardiomyopathy)
I
Intervention
Bucindolol (chronic beta-blocker treatment)
O
Outcome
Left ventricular functionsurrogate

Bucindolol provides a dose-dependent improvement in left ventricular function in patients with heart failure due to systolic dysfunction.

Abstract

In heart failure from systolic dysfunction, beta-blockade with bucindolol produces a dose-related improvement in and prevents deterioration of left ventricular function.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Bristow et al. (1994) studied this question.

synapsesocial.com/papers/69eff904bce9831ba4f73525https://doi.org/10.1161/01.cir.89.4.1632
Ask AI
Helpful
Bookmark
Share
View Full Paper